ADMA Biologics Inc (NASDAQ:ADMA) – Zacks Investment Research cut their Q3 2018 earnings per share estimates for shares of ADMA Biologics in a report issued on Monday, October 15th. Zacks Investment Research analyst J. Vandermosten now forecasts that the biotechnology company will post earnings of ($0.31) per share for the quarter, down from their previous forecast of ($0.29). Zacks Investment Research also issued estimates for ADMA Biologics’ Q4 2018 earnings at ($0.30) EPS and FY2018 earnings at ($1.33) EPS.
ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.03). ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The business had revenue of $4.66 million during the quarter, compared to the consensus estimate of $5.35 million.
Shares of NASDAQ ADMA opened at $5.58 on Thursday. The company has a current ratio of 10.65, a quick ratio of 8.88 and a debt-to-equity ratio of 0.79. ADMA Biologics has a 52-week low of $2.01 and a 52-week high of $6.96. The stock has a market capitalization of $287.83 million, a price-to-earnings ratio of -2.86 and a beta of 2.35.
Several large investors have recently made changes to their positions in ADMA. BlackRock Inc. increased its stake in shares of ADMA Biologics by 59.5% in the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 15,115 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of ADMA Biologics in the first quarter valued at approximately $182,000. Element Capital Management LLC acquired a new stake in shares of ADMA Biologics in the first quarter valued at approximately $118,000. Millennium Management LLC increased its stake in shares of ADMA Biologics by 305.2% in the first quarter. Millennium Management LLC now owns 273,621 shares of the biotechnology company’s stock valued at $1,259,000 after purchasing an additional 206,088 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of ADMA Biologics by 188.0% in the second quarter. Bank of New York Mellon Corp now owns 54,828 shares of the biotechnology company’s stock valued at $247,000 after purchasing an additional 35,791 shares during the period. Institutional investors own 55.08% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.